Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03410732
Other study ID # LAUDC 2017001
Secondary ID
Status Recruiting
Phase Phase 2
First received January 16, 2018
Last updated January 24, 2018
Start date July 1, 2017
Est. completion date December 1, 2020

Study information

Verified date January 2018
Source LanZhou University
Contact Yumin Li, MD, PhD
Phone +8613893615421
Email liym@lzu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Study objectives are to investigate the efficacy and safety of activated autologous dendritic cells (DCs) in treatment of gastric cancer. DCs are activated by the proteins from autologous tumor cell membrane and cytokines in vitro. The efficacy endpoints include objective response, immune-cell response, recurrent rate after a radical surgery, progression-free survival and overall survival, and the safety endpoints include adverse events, laboratory tests, ECG, ECOG-PT, etc.


Description:

Study objectives are to investigate the efficacy and safety of activated autologous dendritic cells (DCs) in treatment of gastric cancer. The autologous DCs are collected and enriched from peripheral blood, and then are activated by the proteins from autologous tumor cell membrane and cytokines in vitro. The efficacy endpoints include objective response, immune-cell response, recurrent rate after a radical surgery, progression-free survival and overall survival, and the safety endpoints include adverse events, laboratory tests, ECG, ECOG-PT, etc. All patients will be followed up for at least 2 years after treatment.


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date December 1, 2020
Est. primary completion date July 1, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

1. Written informed consent given before any trial-specific procedure is initiated

2. Male or female, at least 18 years of age at the time of informed consent

3. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1

4. Life expectancy >3 months assessed during Screening

5. Documented (histologically- or cytologically-proven) gastric cancer that is can be radially removed

Exclusion Criteria:

1. Non-healing wounds on any part of the body

2. Active thrombosis, or a history of deep vein thrombosis or pulmonary embolism, within 1 month prior to surgery, unless adequately treated and stable

3. Active uncontrolled bleeding or a known bleeding diathesis

4. Significant cardiovascular disease or condition, including:

1. Congestive heart failure currently requiring therapy

2. Class III or IV cardiovascular disease according to the New York Heart Association's (NYHA) functional criteria (25)

3. Need for antiarrhythmic medical therapy for a ventricular arrhythmia

4. Severe conduction disturbance (e.g., 3rd degree heart block)

5. Unstable angina pectoris (last episode at least 6 months prior to surgery)

6. Uncontrolled hypertension (per the Investigator's discretion)

7. Myocardial infarction within 6 months prior to C1/D1

5. Abnormal hematologic, renal or hepatic function as defined by the following criteria:

1. Absolute neutrophil count (ANC) <1.5 ×109/L (1500/mm3)

2. Hemoglobin =9 g/dL

3. Platelet count <75 ×109/L (75,000/mm3)

4. Serum creatinine >1.5 × upper limit of normal (ULN) for the institution

5. Aspartate aminotransferase (AST) >3.5 × ULN for the institution or AST >5 × ULN for the institution in case of known liver metastases

6. Alanine aminotransferase (ALT) >3.5 × ULN for the institution or ALT >5 × ULN for the institution in case of known liver metastases

7. Total bilirubin >1.5 × ULN for the institution

8. Prothrombin time as assessed by International Normalized Ratio (INR) >1.5 × ULN for the institution*

9. Partial thromboplastin time (PTT) >1.5 × ULN for the institution*

6. Any of the following within 2 weeks prior to surgery:

1. Any serious or uncontrolled infection

2. Any infection requiring parenteral antibiotics

3. Unexplained fever >38.0 °C

7. Any other life-threatening illness, significant organ system dysfunction, or clinically significant laboratory abnormality, which in the opinion of the Investigator, would either compromise the patient's safety or interfere with the evaluation of the safety of the trial treatment

8. Any kind of disorder that compromises the ability of the patient to give written informed consent and/or to comply with trial procedures or is unwilling or unable to comply with trial requirements at the discretion of the Investigator

9. Breast feeding, or plans by the patient (or the patient's partner) to become pregnant during treatment or within 4 months after the end of treatment

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
activated DCs
autologous dendritic cells are collected and enriched from 50 ml of peripheral blood, then activated by autologous tumor cell membrane proteins. Then the activated DCs are iv infused in 21 days after a radical surgery.
Procedure:
radical surgery only
Only radical surgery is given to the control group

Locations

Country Name City State
China Lanzhou University Second Hospital Lanzhou Gansu

Sponsors (1)

Lead Sponsor Collaborator
LanZhou University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary progression-free survival Time to progression/death or censored time 3 years
Secondary recurrent rate the rate of cancer recurring after surgery 3 years
Secondary overall survival rate time to death or censored time 5 years
Secondary immune-cells response CD4/CD8 T lymphocyte percentage change 3 months
Secondary Adverse event rate Adverse event rate 3 months
See also
  Status Clinical Trial Phase
Recruiting NCT05551416 - The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer
Completed NCT05518929 - Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients Phase 4
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT03219593 - Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Recruiting NCT05536102 - The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy) Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Recruiting NCT05415098 - Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas Phase 1
Active, not recruiting NCT04082364 - Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer Phase 2/Phase 3
Withdrawn NCT03766607 - Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer Phase 2
Recruiting NCT04118114 - Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors Phase 2
Completed NCT01924533 - Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer. Phase 3
Terminated NCT01641939 - A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Phase 2/Phase 3
Recruiting NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies Phase 1
Active, not recruiting NCT04908813 - Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer Phase 2
Active, not recruiting NCT04249739 - Pembrolizumab + Capecitabine/Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive Phase 2
Recruiting NCT05514158 - To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG) Phase 1
Recruiting NCT04931654 - A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer Phase 1/Phase 2
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2